A new study has shown that while there was an increase in the percentage of women diagnosed with early-stage breast cancer undergoing a double mastectomy, the increase was not associated with a lower risk of death compared to breast-conserving surgery plus radiation.
The American Society of Clinical Oncology (ASCO) has released a new clinical practice guideline on the treatment of patients with advanced HER2-negative breast cancer.
Helpful eating tips for women who are going through breast cancer treatment
Although lung cancer incidence is decreasing in the United States, the details about this trend are unknown.
The National Pancreas Foundation (NPF), a nonprofit organization that provides hope for those suffering from pancreatitis and pancreatic cancer, has announced that it will build the first-ever national patient registry devoted to all pancreatic diseases, including pancreatic cancer and pancreatitis.
Every year, Cancer Hope Network (CHN) awards a group or individual who has made a difference through their own courageous battle with cancer, or who has helped others through the ordeal of treatment. The Committee evaluates nominees on how they made a difference through a display of courage, spirit, inspiration, or support in the battle with cancer.
Patients starting palliative care for advanced cancer are often already on repeat prescriptions of statins to lower cholesterol and reduce risk of a heart attack or stroke, and many of these patients continue on statin therapy until death.
A randomized multi-center trial examining the efficacy of adding the prohormone dehydroepiandosterone (DHEA) to a vaginal bioadhesive moisturizer in postmenopausal survivors of breast or gynecologic cancer has found that daily rather than as-needed use of such a moisturizer significantly relieves symptoms of vaginal atrophy in these women, and that when DHEA is added, survivors report significant improvements in sexual desire, arousal, pain, and overall sexual function.
The FDA has approved eltrombopag (Promacta) as a treatment for patients with severe aplastic anemia (SAA) following an insufficient response to immunosuppressive therapy, based on data from an open-label, single-arm phase II trial.
The novel agents idelalisib and ABT-199 in combination with rituximab have demonstrated impressive activity with manageable toxicity for patients with relapsed or refractory chronic lymphocytic leukemia
As the clock ticks closer to the January 1, 2015 deadline for the implementation of the new Commission on Cancer (CoC) standards, I've been asking nurses and patient navigators this question: What are you going to focus on come January 2, 2015 and beyond? What's next?
Frontline therapy with bevacizumab or cetuximab combined with either FOLFOX or FOLFIRI yielded a comparable survival benefit of approximately 29 months in patients with KRAS wild-type metastatic colorectal cancer (mCRC), according to results from the phase III CALGB/SWOG 80405 trial.
Men diagnosed with prostate cancer after being diagnosed with depression were less likely to undergo definitive treatment for their cancer and had worse overall survival
New research has found that high risk and minority women receive better cancer care if they are paired with a patient navigator.
We need to either do away with the pink or change the color for inflammatory breast cancer (IBC), because it's not at all pink. It's black and blue, purple, and sometimes just plain red.
Two studies and a commentary published this week suggest that too much of a good thing can actually be a bad thing when cancer screening is involved.
Even though universal coverage for postmastectomy breast reconstruction is mandated, a new study has found that the majority of women are deciding not to undergo breast reconstruction surgery following a mastectomy.
Researchers at The University of Texas at Austin have found that postmenopausal overweight or obese breast cancer patients receiving hormone therapy as part of their treatment who use nonsteroidal anti-inflammatory drugs (NSAIDs) have significantly lower breast cancer recurrence rates and a sizable delay in time to cancer recurrence.
Results of a large, pooled analysis indicate that there is a link between a number of common respiratory diseases and an increase in the risk of developing lung cancer.
Cologuard is indicated to screen adult men and women aged 50 years or older who are at typical average-risk for CRC
The FDA has approved bevacizumab (Avastin) in combination with paclitaxel and cisplatin or paclitaxel and topotecan as a treatment for patients with persistent, recurrent, or metastatic cervical cancer
The deadline for our 2014 grant cycle recently passed, and in the many hundreds of applications received, we heard a similar story: being cancer-free doesn't mean that cancer IS free.
I believe mastering conversation strategies via social media is as essential to today's nursing practice as our stethoscopes and our brain. Why?
The National Pancreas Foundation (NPF) provides hope for those suffering from pancreatitis and pancreatic cancer through funding cutting-edge research, advocating for new and better therapies, and providing support and education for patients, caregivers, and healthcare professionals.
According to researchers at the University of Washington, the benefits of mammography extend to women older than 75 years, and the findings have the potential to change public health recommendations for breast cancer screening.
A growing understanding of the biological pathways at work in the development of oral mucositis in patients treated with cytotoxic cancer therapies has helped spur interest in steering symptom management away from "institutional folklore" rinses and anecdotal approaches toward evidence-based strategies
The FDA has approved Cologuard as the first noninvasive stool-based DNA test for the detection of colorectal cancer (CRC) in asymptomatic individuals at average risk, based on clinical trial results demonstrating superiority to the fecal immunochemical test (FIT).
A new study has found that postmenopausal women who undertook regular physical activity equivalent to at least 4 hours of walking per week in the last 4 years had a lower risk for invasive breast cancer compared with women who exercised less during those 4 years.
An expert panel and focus groups in Michigan created Guidelines for the Primary Care Management of Prostate Cancer Post-Treatment Sequelae in 2009 and published an update in July 2014.
In this podcast, Brian Wojciechowski, MD, Breastcancer.org medical adviser, discusses some of the research that was published in July 2014.
